 |
|
HOME » INVESTORS
QUICK LINKS
FACT SHEET (PDF)
CORPORATE PRESENTATION (PDF)
STOCK QUOTE (TSX)
OUR STRATEGY
- Establish a prominent drug development company
- Bring the company's founding technology in antimicrobial peptides to its optimal commercial potential
- Diversify the technology base, expand the product pipeline, and grow the company through acquisitions and in-licensing
- Form late stage strategic alliances and early stage corporate research collaborations
- Focus in-house activities on product development strengths
- Maintain and augment a strong financial position
|
|
OUR BUSINESS MODEL
The business model of the Company is focused on developing products from the post-discovery stage (e.g. lead identification and optimization) through to mid-stage clinical development. In most cases, the Company intends to partner product candidates after preliminary efficacy is obtained (typically in late Phase II). In addition, the company is actively pursuing earlier stage corporate research collaborations with companies where the combination of technologies, resources, and expertise can advance product candidates more effectively.
Internally, the company will focus primarily on its strengths in
research and product development. Employing internal resources in this
way, the company will look to use third party expertise to more
efficiently and cost-effectively advance its non-core activities. This
will enable the research and development team to concentrate mainly on
adding and moving product candidates more effectively through the
development process. |
